{"id":"W4381612716","doi":"10.1200/jco.22.02746","title":"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Sanofi","keywords":"Medicine; Internal medicine; Hazard ratio; Estrogen receptor; Oncology; Breast cancer; Fulvestrant; Cancer; Progression-free survival; Clinical endpoint; Gynecology; Clinical trial; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00219677,0.001756493,0.0023449,0.000491056,0.0004028822,0.0009292251,0.0008235105,0.001596751,0.006344697],"category_scores_gemma":[0.001817605,0.0006559826,0.001434664,0.0004677655,0.001418823,0.001124944,0.000437639,0.002674809,0.001082927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007372051,"about_ca_system_score_gemma":0.001536842,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006811607,"about_ca_topic_score_gemma":0.002208554,"domain_scores_codex":[0.9992436,0.0004271348,0.00004372913,0.0001378535,0.00005050319,0.00009717519],"domain_scores_gemma":[0.9990712,0.0002722572,0.0001991593,0.00007406234,0.00004985159,0.0003333341],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9699322,0.01203136,0.0005860047,0.000323884,0.000390249,0.00003122357,0.0000462574,0.000417047,0.003114335,0.0001470541,0.0007147926,0.0122656],"study_design_scores_gemma":[0.9239813,0.07360718,0.000809555,0.00001254491,0.0001611313,0.00002556731,0.00001000898,0.0004134935,0.0003575614,0.0001283959,0.0004823558,0.00001089021],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826136,0.002640671,0.000926168,0.0005449619,0.0004894314,0.008777685,0.001447963,0.0001426352,0.002416868],"genre_scores_gemma":[0.9785795,0.001997882,0.002092915,0.001267154,0.0004904689,0.01033542,0.001375252,0.0000396448,0.00382181],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006344697,"threshold_uncertainty_score":0.02122515,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08678585079797575,"score_gpt":0.4766479143054478,"score_spread":0.389862063507472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}